Where do CRISPR Therapeutics's ratios come from?

Every ratio is computed from CRISPR Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Operating margin	-15,754.2%+3,179pp	-18,933.6%-17,435pp	-1,498.3%-46.3pp	-1,451.9%-193pp	-1,259.2%-8.8pp
Net margin	-13,856.5%+2,713pp	-16,569.8%-15,296pp	-1,273.7%-44.3pp	-1,229.4%-206pp	-1,023.6%-42.1pp
EBITDA margin	-15,289.6%+3,089pp	-18,378.7%-16,929pp	-1,449.6%-47.5pp	-1,402.1%-194pp	-1,208.3%-9.6pp
Free cash flow margin	-9,777.6%+77.9pp	-9,855.5%-9,065pp	-790.7%+64.9pp	-855.6%-38.5pp	-817.1%-429pp
Returns
Return on equity	-31.2%-1.0pp	-30.2%-4.9pp	-25.3%0.0pp	-25.3%-5.6pp	-19.7%-0.5pp
Return on assets	-23.2%+2.6pp	-25.8%-4.1pp	-21.7%-0.3pp	-21.4%-4.7pp	-16.7%-0.4pp
Return on invested capital	-32.4%+4.1pp	-36.5%-6.2pp	-30.4%+1.6pp	-31.9%-4.2pp	-27.7%-1.7pp
Efficiency
Asset turnover	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Liquidity
Current ratio	18×+4.6×	13.3×-2.9×	16.2×-0.4×	16.6×+1.0×	15.6×-6.4×
Quick ratio	18×+4.6×	13.3×-2.9×	16.2×-0.4×	16.6×+1.0×	15.6×-6.4×
Cash ratio	3.1×+0.8×	2.3×-0.1×	2.4×+0.6×	1.9×-0.1×	2×-1.4×
Leverage
Debt-to-equity	0.4×+0.3×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Debt-to-assets	0.3×+0.2×	0.1×0.0×	0.1×0.0×	0.1×0.0×	0.1×0.0×
Per Share
Book value per share	$18.89-11.6%	$21.37+1.8%	$20.98+6.8%	$19.65-7.7%	$21.28-7.1%
Valuation
Market capitalization	$4.57B-8.6%	$5B-15.2%	$5.89B+45.9%	$4.04B+38.4%	$2.92B-13.1%
Enterprise value	$4.93B+1.5%	$4.86B-16.5%	$5.82B+43.3%	$4.06B+39.9%	$2.9B-11.6%
Price / sales	1,112.8×-311×	1,423.8×+1,270×	153.8×+47.6×	106.2×+28.7×	77.5×-12.6×
Price / book	2.5×-0.1×	2.6×-0.5×	3.1×+0.7×	2.4×+0.8×	1.6×-0.1×
EV / sales	1,201.6×-182×	1,383.7×+1,232×	151.8×+45.0×	106.8×+29.7×	77.1×-11.0×
Free cash flow yield	-8.8%-1.9pp	-6.9%-1.8pp	-5.1%+2.9pp	-8.1%+2.5pp	-10.5%-6.2pp
Earnings yield	-12.5%-0.8pp	-11.6%-3.4pp	-8.3%+3.3pp	-11.6%+1.6pp	-13.2%-2.3pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about CRISPR Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

Where do CRISPR Therapeutics's ratios come from?: Every ratio is computed from CRISPR Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.